Related Experiment Videos
A basic conceptual and practical overview of interactions with highly prescribed drugs
George K Dresser1, David G Bailey
1Department of Medicine, University of Western Ontario, Lawson Health Research Institute, London, Canada.
Summary
Drug interactions often stem from altered drug elimination via cytochrome P450 enzymes (CYPs) and P-glycoprotein. Understanding these mechanisms can predict and prevent adverse drug events by managing drug combinations and patient factors.
Area of Science:
- Pharmacology
- Drug Metabolism
- Drug Interactions
Background:
- Drug elimination pathways, including cytochrome P450 enzymes (CYPs) and P-glycoprotein, are crucial for drug efficacy and safety.
- Altered activity of these pathways can lead to adverse drug interactions, manifesting as reduced therapeutic benefit or increased toxicity.
Purpose of the Study:
- To review the characteristics of key drug-metabolizing enzymes (CYPs) and drug transporters (P-glycoprotein).
- To discuss substrates, inducers, inhibitors, and associated adverse events for CYPs and P-glycoprotein.
- To explore strategies for predicting and preventing drug interactions.
Main Methods:
- Review of literature on drug elimination mechanisms, focusing on CYPs and P-glycoprotein.
- Analysis of drug properties influencing interactions, including bioavailability and elimination pathways.
- Discussion of patient-specific factors and administration methods affecting susceptibility to adverse events.
Main Results:
- Detailed profiles of major CYP enzymes (CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2) and P-glycoprotein, including their substrates, inducers, and inhibitors.
- Identification of common drug interactions and their clinical consequences (induction or inhibition of elimination).
- Prediction of interaction potential based on drug and patient characteristics.
Conclusions:
- Drug interactions involving CYPs and P-glycoprotein are predictable and preventable.
- Avoiding concomitant administration of interacting drugs or employing alternative therapies can mitigate risks.
- Patient-specific factors and drug administration methods significantly influence susceptibility to adverse drug events.